Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

被引：4

作者：

Cao, M. Gonzalez ^{[1
]}

Viteri, S. ^{[1
]}

Garran, C. ^{[1
]}

Nieto, Y. ^{[1
]}

Aristu, J. ^{[1
]}

Ponz, M. ^{[1
]}

Algarra, S. Martin ^{[1
]}

机构：

[1] Univ Navarra Clin, Dept Oncol, Pamplona 31008, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2007年 / 9卷 / 02期

关键词：

taxol; bevacizumab; melanoma;

D O I：

10.1007/s12094-007-0023-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We report here a taxol - bevacizumab-responsive metastatic melanoma case. Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.

引用

页码：119 / 120

页数：2

共 7 条

[1]

Campone M, 2002, B CANCER, V89, P275

[2]

Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer [J].

Kabbinavar, FF ;

Hambleton, J ;

Mass, RD ;

Hurwitz, HL ;

Bergsland, E ;

Sarkar, S .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3706-3712

[3]

LEGHA SS, 1990, CANCER, V65, P2478, DOI 10.1002/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO

[4]

2-S

[5]

MILLER KD, 2005, BREAST CANC RES S1, V94, P792

[6]

Phase II study of thalidomide in patients with metastatic melanoma [J].

Pawlak, WZ ;

Legha, SS .

MELANOMA RESEARCH, 2004, 14 (01) :57-62

[7]

Sandler A. B., 2005, J CLIN ONCOL, V23, pLBA4, DOI [10.1200/jco.2005.23.16_suppl.lba4, DOI 10.1200/JCO.2005.23.16_SUPPL.LBA4]

← 1 →